Last updated 2026-06-18
- Acquired by AnGes, Dec 2020
- Raised $61M funding round, Jan 2020
- Raised $12M funding round, Oct 2016
Total raised
$73.0M
Last: 2020-01
Stage
Acquired
Founded
2015
Headcount
42
HQ
, Israel
Sector
Health Tech & Life Sciences
About
Emendo Biotherapeutics develops next-generation gene-editing tools for genetic disorders, addressing technological gaps for realizing the promise of gene therapy.
Emendo genome-editing technology can repair and eliminate genetic mutations in living cells that cause serious diseases or disorders. Emendo's gene-editing solutions are recombination based, highly specific, and have zero off-target effect.
Funding history · 2 rounds · $73.0M total
2020-01
$61.0M
2016-10
$12.0M
Q&A
- What is Emendo Biotherapeutics' primary focus?
- Emendo Biotherapeutics focuses on DNA Correction and Genome-editing Platforms, developing next-generation gene-editing tools for genetic disorders.
- When was Emendo Biotherapeutics founded?
- Emendo Biotherapeutics was founded in May 2015.
- What is the current status of Emendo Biotherapeutics?
- Emendo Biotherapeutics was acquired by AnGes in December 2020.
- How much funding did Emendo Biotherapeutics raise in total before its acquisition?
- Emendo Biotherapeutics raised a total of $73,000,000.
- Which investors participated in Emendo Biotherapeutics' January 2020 funding round?
- In January 2020, Emendo Biotherapeutics received funding from OrbiMed and Takeda Ventures.
- What is the employee count for Emendo Biotherapeutics?
- Emendo Biotherapeutics has 11-50 employees.
- Where is Emendo Biotherapeutics headquartered?
- Emendo Biotherapeutics is headquartered in Ness Ziona, Israel, with an additional office in New York, USA.
- What is Emendo Biotherapeutics' core technology?
- Emendo Biotherapeutics' core technology involves recombination-based gene-editing solutions that are highly specific and aim for zero off-target effects to repair and eliminate genetic mutations.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
genome-editinggene-editingbiopharmaceuticalgenomics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | emendobio.com/ |
|---|---|
| linkedin.com/company/10443839 |
Identifiers & details
| Founded | 2015-5 |
|---|---|
| Employees (exact) | 42 |
| Offices | New York |
| Status reason | Acquired by AnGes on Dec, 2020 |
Acquisitions & public offerings
Acquired by AnGes 2020-12
Radar intelligence
Web history (Wayback)
| Domain | emendobio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|